1097628-00-6

Basic information

• Product Name: 3-[[3-ethyl-1,2,3,6-tetrahydro-5-(1-methylethyl)-2,6-dioxo-4-pyrimidinyl]carbonyl]-5-methylbenzonitrile
• Synonyms: 3-[[3-ethyl-1,2,3,6-tetrahydro-5-(1-methylethyl)-2,6-dioxo-4-pyrimidinyl]carbonyl]-5-methylbenzonitrile
• CAS NO: 1097628-00-6
• Molecular Weight: 325.367
• Mol File: 1097628-00-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-[[3-ethyl-1,2,3,6-tetrahydro-5-(1-methylethyl)-2,6-dioxo-4-pyrimidinyl]carbonyl]-5-methylbenzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[[3-ethyl-1,2,3,6-tetrahydro-5-(1-methylethyl)-2,6-dioxo-4-pyrimidinyl]carbonyl]-5-methylbenzonitrile(1097628-00-6)
• EPA Substance Registry System: 3-[[3-ethyl-1,2,3,6-tetrahydro-5-(1-methylethyl)-2,6-dioxo-4-pyrimidinyl]carbonyl]-5-methylbenzonitrile(1097628-00-6)

Safety Data

• Hazardous Substances Data: 1097628-00-6(Hazardous Substances Data)

Upstream product

• 1236311-96-8 C₁₂H₉N₃O 
• 1236311-95-7 C₉H₁₃BrN₂O₂ 
• 1205514-04-0 3-cyano-5-methyl-benzoyl chloride 
• 1006300-12-4 3-(5-isopropyl-2,6-dioxo-1,2,3,6-tetrahydro-pyrimidine-4-carbonyl)-5-methyl-benzonitrile 
• 75-03-6 ethyl iodide 
• 1006300-03-3 6-(3-bromo-5-methylbenzoyl)-5-isopropylpyrimidine-2,4(1H,3H)-dione 
• 557-21-1 dicyanozinc 
• 1006300-01-1 (3-bromo-5-methyl-phenyl)-(5-isopropyl-2,6-dimethoxy-pyrimidin-4-yl)-acetonitrile 

Downstream Products

• 1097628-87-9 3-[(3-ethyl-5-isopropyl-2,6-dioxo-1,2,3,6-tetrahydro-pyrimidin-4-yl)-hydroxy-methyl]-5-methyl-benzonitrile 
• 1099828-41-7 4-(3-Cyano-5-methylbenzoyl)-3-ethyl-5-isopropyl-2,6-dioxo-2,3-dihydropyrimidin-1(6H)-ylmethyl acetate 
• 1099828-39-3 C₂₇H₃₈N₃O₇P 
• 1099828-46-2 C₂₃H₂₇N₃O₆ 

Relevant articles and documents

PROCESSES FOR PREPARING HIV REVERSE TRANSCRIPTASE INHIBITORS

Disclosed is a method for preparing HIV reverse transcriptase inhibitors which inhibit replication of HIV in HIV infected cells, and novel intermediate compounds used therein.

NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS

The invention is related to compounds of Formula (I) or a pharmaceutically acceptable salt, solvate, ester, and/ or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.